Artificial intelligence and precision medicine company Tempus is partnering with the Children's Oncology Group to study genetic testing-directed treatment in pediatric patients with solid tumors and non-Hodgkin lymphomas and histiocytic disorders.
Tempus will provide genomic sequencing technology to up to 300 patients per year between the ages of 12 months and 21 years. Clinicians will have access to Tempus' xT assay technology to help identify if patients are eligible for the Children's Oncology Group's Pediatric MATCH screening trial, according to the Sept. 20 Tempus news release.
"The Children's Oncology Group is a leader in pediatric oncology research, and we are excited to support their efforts in providing pediatric cancer patients expanded access to personalized care," said Kristiyana Kaneva, MD, a pediatric oncologist and senior medical director of clinical development at Tempus. "This collaboration will allow more pediatric patients to access genomic sequencing, which is critical for planning their treatment journey and for matching these children, adolescents, and young adults to clinical trials."